Biolojic Design

Biolojic Design is a private, preclinical-stage biotech leveraging a proprietary AI/ML platform to engineer next-generation antibody therapeutics. The company's core innovation is designing 'programmable antibodies' that can act as dynamic functional switches, such as epitope-specific binders and symmetrical multi-specific 'Multibodies,' aiming for greater precision, efficacy, and lower toxicity. It has established key partnerships with Teva Pharmaceuticals and Johnson & Johnson Innovation (JLABS) and is advancing a pipeline targeting validated pathways in autoimmunity and cancer. The company is led by a team with expertise spanning computational biology, AI, and drug development.

Proprietary AI/ML platform that mimics the immune system to design programmable human antibodies. It uses a vast proprietary dataset to identify template antibodies and suggest mutations to create epitope-specific antibodies (agonists, antagonists, etc.) and symmetrical multi-specific 'Multibodies.' The platform iteratively refines designs using high-throughput experimental data and dedicated machine learning models.

Biolojic operates in the highly competitive field of AI-driven drug discovery, competing with other antibody-focused AI biotechs like Absci, BigHat Biosciences, and LabGenius, as well as internal efforts at large pharmaceutical companies. Its differentiation lies in its specific focus on programming functional outcomes (e.g., agonism) and its proprietary Multibody format for multi-specificity.